Background: Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, and it is a significant global health problem causing significant morbidity and mortality. Long noncoding RNAs (lncRNAs) have been identified as a class of gene expression regulators that play a critical role in the immune system. However, the function of lncRNAs in the immune microenvironment of ccRCC remains unclear.
Methods: The least absolute shrinkage and selection operator regression techniques, robust likelihoodbased survival modeling, and Cox regression analysis were used to identify potential prognostic lncRNAs. The relationship between the signature and the tumor's immune infiltration was analyzed using gene set enrichment analysis and the subset analysis of immune cells.
Results: LINC00839, LINC01671, AC093673, and AC008760 were selected to create a risk signature. For 3-, 5-, and 8-year overall survival rates, the areas under the receiver operating characteristic curves of the risk signature set were 0.689, 0.721, and 0.719 in the training set and 0.683, 0.686, and 0.665 in the validation set, respectively. A model and nomogram were constructed using the risk signature and clinical characteristics. The C-index of the model was 0.78 in the training set and 0.773 in the validation set.
Conclusion: The risk signature reflects the tumor's current immune infiltration and is associated with regulatory T cell differentiation, interleukin 17 production regulation, negative regulation of inflammatory response to an antigenic stimulus, and the IL6-JAK-STAT3 signaling pathway. This study provides prognostic information for ccRCC patients and may also serve as a useful clue for future immunotherapies.
[http://dx.doi.org/10.2215/CJN.00990119] [PMID: 31672794]
[http://dx.doi.org/10.1038/s41590-018-0207-y] [PMID: 30224822]
[http://dx.doi.org/10.1186/s13059-016-1092-z] [PMID: 27855702]
[http://dx.doi.org/10.1038/s41467-020-14802-2] [PMID: 32081859]
[http://dx.doi.org/10.1200/JCO.2012.41.5984] [PMID: 23358969]
[http://dx.doi.org/10.1073/pnas.0506580102] [PMID: 16199517]
[http://dx.doi.org/10.1016/j.eururo.2012.07.028] [PMID: 22841673]
[http://dx.doi.org/10.1016/j.cell.2019.10.007] [PMID: 31675502]
[http://dx.doi.org/10.3390/cancers12020300] [PMID: 32012804]
[http://dx.doi.org/10.1007/s10147-020-01632-x] [PMID: 32048086]
[http://dx.doi.org/10.2147/CMAR.S269774] [PMID: 33061593]
[http://dx.doi.org/10.3389/fcell.2021.657667] [PMID: 33855028]
[http://dx.doi.org/10.1007/s12010-019-03082-2] [PMID: 31422559]
[http://dx.doi.org/10.1038/ni.3868] [PMID: 29083399]
[http://dx.doi.org/10.1158/1078-0432.CCR-15-0858] [PMID: 27001312]